Medical writer: Jasenka Piljac Žegarac, PhD
Significantly longer overall survival (OS) was observed in women treated with endocrine therapy (ET) plus ribociclib, compared with women treated with ET alone, in the phase III MONALEESA-7 trial of premenopausal women with HR+/HER2-negative advanced breast cancer (ABC). This is the first study demonstrating significantly longer OS in patients treated with a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor plus ET combination, compared to ET alone, as initial endocrine-based therapy.
“MONALEESA-7 was the first phase III trial with a CDK4/6 inhibitor [conducted] exclusively in premenopausal patients,” said Sara A. Hurvitz, MD, of the University of California, Los Angeles, Jonsson Comprehensive Cancer Centre, on June 4 (Abstract LBA1008).
A total of 672 premenopausal women with HR+/HER2-negative ABC who had not received ET for metastatic disease or who had received up to one prior line of chemotherapy were rand...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Overcoming the Challenges of Immunotherapy in Non–small Cell Lung Cancer Next Article
Benefits Seen with Apalutamide plus Adt in Metastatic Castration-sensitive Prostate Cancer »
Table of Contents: ASCO 2019
Head and Neck Cancer
Genitourinary Cancer - Prostate Cancer
Developmental Therapeutics - Immunotherapy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.